Interpace Diagnostics (NASDAQ: IDXG) shares are 7% higher in mid-morning trade on news that the company has signed a new national contract with Aetna for its ThyGenX® and ThyraMIR® molecular tests for indeterminate thyroid nodules. The agreement goes into effect August 15, 2017, and will include many of Aetna’s products, such as commercial and Medicare Advantage plans. However, it does not include Medicaid, auto insurance, or workman’s compensation products. The agreement marks Interpace’s first national provider contract with a national health plan and makes the company a part of Aetna’s laboratory network for these services. “Coverage of our thyroid products has continued to increase and improve over the past few quarters and now totals over 250 million covered lives,” Interpace president and CEO Jack E. Stover stated in the news release.
To view the full press release, visit: http://nnw.fm/Low2V
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The company currently has three commercialized molecular tests; PancraGen® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics’ mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information, visit www.interpacediagnostics.com
About NetworkNewsBreaks
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
